DelveInsight, a leading market research and consulting firm, has recently published an in-depth report on the Dengue Fever pipeline, providing valuable insights into emerging therapies, companies, and future outlooks.
DelveInsight’s, “Dengue Fever Pipeline Insight 2023” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Dengue Fever pipeline landscape. It covers the Dengue Fever pipeline drug profiles, including Dengue Fever clinical trials and nonclinical stage products. It also covers the Dengue Fever therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
To explore more information on the latest breakthroughs in the Dengue Fever Pipeline treatment landscape of the report, click here @ Dengue Fever Pipeline Outlook
Key Takeaways from the Dengue Fever Pipeline Report
For further information, refer to the detailed Dengue Fever Unmet Needs, Dengue Fever Market Drivers, and Dengue Fever Market Barriers, click here for Dengue Fever Ongoing Clinical Trial Analysis
Dengue Fever Overview
Dengue Virus (DENV) is an arbovirus (arthropod-borne virus). Four serotypes of DENV are responsible for the infectious disease called dengue which annually affects nearly 400 million people worldwide. Dengue fever is a common mosquito-borne illness in many tropical and subtropical countries.
Request a sample and discover the recent advances in Dengue Fever Ongoing Clinical Trial Analysis and Medications, click here @ Dengue Fever Treatment Landscape
Dengue Fever Emerging Drugs Profile
Takeda’s TAK-003 is an investigational live-attenuated tetravalent dengue vaccine, that prevents dengue fever caused by any of the four serotypes of the dengue virus of which can cause dengue fever or Severe Dengue. Takeda’s current clinical development program consists of five Phase 3 trials of TAK003 Clinical Phase 1 and 2 data in children and adolescents showed that TAK-003 induced immune responses against all four dengue serotypes.
Merck & Co’s adjuvanted, tetravalent subunit vaccine V180 comprises truncated forms of envelope proteins (DEN-80E), derived from strains of all four dengue virus serotypes. The DEN-80E subunits are expressed from plasmids in the Drosophila S2 cell expression system and are formulated with either ISCOMATRIX or Alhydrogel.V180’s more compact dosing schedule could make it a more attractive alternative to Dengvaxia, particularly for travelers. However, its current three-dose schedule could still be improved to reduce the risk of non-compliance. It is believed that V180 would achieve its greatest commercial potential as part of a heterologous prime-boost strategy with TetraVax-DV. V180 is currently in Phase I development.
AV-1 is a human monoclonal antibody (mAb) being investigated as a potential therapy for dengue, a mosquito-borne viral disease with extensive global public health impact. Currently, Av1 is being studied in phase I in adult healthy individuals.
Dive deep into rich insights for drugs for Dengue Fever Market Drivers and Dengue Fever Market Barriers, click here @ Dengue Fever Unmet Needs and Analyst Views
Dengue Fever Pipeline Therapeutics Assessment
There are approx. 10+ key companies are developing Dengue Fever therapies. The Dengue Fever companies which have their Dengue Fever drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Takeda and others.
Scope of the Dengue Fever Pipeline Report
Got Queries? Find out the related information on Dengue Fever Mergers and acquisitions, Dengue Fever Licensing Activities @ Dengue Fever Emerging Drugs, and Recent Trends
Table of Content
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/consulting-services